Authorization

Cellectis Reports 4th Quarter and Full Year 2018 Financial Results

Regulatory News:


Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS -
Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on
developing immunotherapies based on gene-edited allogeneic CAR T-cells
(UCART), today announced its results for the fourth quarter 2018 and
full year ended December 31, 2018.
















Earnings Call Details


















Cellectis to hold a conference call for investors on March 12, 2019
at 7:30 a.m. EDT a?? 12:30 p.m. Central European Time (CET). The call
will include the Company's fourth quarter 2018 and year-end
financial results.

















The live dial-in information for the conference call is:








US & Canada only: 877-407-3104








International: 201-493-6792








In addition, a replay of the call will be available for 6 months
following the conference by calling 877-660-6853 (Toll Free US &
Canada); 201-612-7415 (Toll Free International).






1 Cash position includes cash, cash equivalents and current
financial assets
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2019    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
3031